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Abstract 
This year over 230,000 women worldwide will be diagnosed with ovarian cancer, 
and 150,000 will die from this disease, making ovarian cancer the most lethal 
gynecologic cancer.  While many cancers like lung, breast and prostate cancer have 
enjoyed amazing progress in the past 50 years, ovarian cancer mortality has remained 
high due to late detection, lack of novel treatment approaches and lack of prevention 
options.  With the advent of genetic testing, we have an opportunity to reduce mortality 
by better understanding ovarian cancer contributing factors and developing prevention or 
early detection measures.  Effective screening programs are desperately needed to 
identify cancer cases before late stage advancement.  Lastly, many improved treatment 
options are currently in clinical trials, including approaches to engage the immune 
system to better reduce cancerous cell growth.  Improving ovarian cancer survival rates 
will require a shift in how research funds are allocated, shifting government funds from 
treatment toward researching effective preventing and screening measures.
Introduction 
Ovarian cancer is the seventh most common cancer in women with over 230,000 
new cases annually worldwide (International Agency for Research on Cancer, 2013) and 
the fourth leading cause of cancer-related death for women in developed countries 
(Jayson, Kohn, Kitchener, & Ledermann, 2014).  In over 80% of newly diagnosed cases, 
ovarian cancer has reached Stage IIIC or IV, where malignant tumors have spread 
through or beyond the abdominal cavity (Chester, Dorigo, Berek, & Kohrt, 2015).  As 
significant treatment advances have been made for many types of cancer, the standard 
treatment for ovarian cancer has remained nearly the same for the past 20 years.  While 
genetic correlations have been found for approximately 23% of ovarian cancer cases 
(Toss et al., 2015), very little is known about the causes of this type of cancer.   
Through this research paper we will review ovarian cancer background and 
current standards of care.  We will then explore what can be done to reduce ovarian 
cancer mortality through three specific research questions:  
1) Prevention: What risk factors can be leveraged to apply prevention measures? 
2) Detection: How can more ovarian cancer cases be detected earlier? 
3) Treatment: Can new treatment approaches improve overall survival? 
Each of these questions will be covered in the Prevention, Screening, and Treatment 
sections, respectively.  Lastly, we will close with a summary of proposed research 
funding adjustments that can ultimately reduce ovarian cancer cases and improve 
overall outcomes for women diagnosed with ovarian cancer. 
 
 
 
 
 
Background 
Cancer is a condition of uncontrolled cell growth.  If the cells acquire the ability to 
invade tissue, the cancerous cells are considered malignant.  The concern is that 
malignant cancer can impede normal organ function and threaten the life of the “host”.  
Carcinoma is a type of cancer that originates from epithelial cells.  Epithelial cells are 
present on the lining of ovaries, fallopian tubes and the peritoneal membrane (a thin 
membrane that lines the abdominal cavity). The term “ovarian cancer” in this paper is 
used to describe epithelial carcinomas that originate from any of the three locations 
below: 
1) Ovarian Carcinoma – originates on the outer layer of the ovaries. 
2) Fallopian Tube Carcinoma – originates on the distal fallopian tubes between 
ovaries and the uterus. 
3) Primary Peritoneal Carcinoma (PPC) – originates in the peritoneal membranes 
surrounding the organs in the lower abdominal cavity. 
All three types of epithelial carcinoma (ovarian, tubal, and peritoneal) use the 
same staging criteria as defined by the International Federation of Gynecology and 
Obstetrics (FIGO).  Table 1 contains a description of each stage and the expected >5 
year survival rates.  Since ovarian cancer does not become symptomatic until the 
disease has progressed, over 80% of cases are diagnosed at Stage III and nearly 15-
20% of cases are diagnosed at Stage IV (Prat, 2015).   
 
 
 
 
Table 1 - Epithelial Ovarian Cancer Stage Scoring with 5 year expected survival rates 
Stage Description1 5 year survival2 
Stage I  Tumor confined to ovaries or fallopian tube(s) 90% 
Stage II  Tumor involves 1 or both ovaries or fallopian tubes 
with pelvic extension (below pelvic brim) or primary 
peritoneal cancer  
70% 
Stage III  Tumor involves 1 or both ovaries or fallopian tubes, 
or primary peritoneal cancer, with cytologically or 
histologically confirmed spread to the peritoneum 
outside the pelvis and/or metastasis to the 
retroperitoneal lymph nodes 
39% 
Stage IV  Distant metastasis excluding peritoneal metastases 17% 
1(Prat, 2015); 2(American Cancer Society, 2015) 
FIGO also recommends determining the carcinoma cell type during the staging 
diagnosis to aide treatment decisions.  At least five distinct carcinoma types can be 
determined based on visual pathological analysis of a biopsy of the cancerous tumor 
(Prat, 2015): 
1) High Grade Serous Ovarian Cancer (HGSOC) - 70% of cases 
2) Low Grade Serous Ovarian Cancer (LGSOC) – 5% of cases 
3) Mucinous Ovarian Cancer – 3% of cases 
4) Clear Cell Ovarian Cancer – 10% of cases 
5) Endometroid Ovarian Cancer – 10% of cases 
Figure 1 displays the five carcinoma cell types and the current treatment strategy.  For 
the most part, treatment is the same regardless of the carcinoma type.   
 Figure 1 – Current Treatment Strategy for Ovarian Cancer (Lheureux, Karakasis, Kohn, & Oza, 
2015) 
For over 20 years, the standard of care for “ovarian cancer” has included a 
“debulking” surgery followed by six rounds of platinum based chemotherapy.  More 
recently, surgeons may recommend chemotherapy prior to surgery (called neoadjuvant 
chemotherapy) based on the results of two studies showing improved surgical outcomes 
without changes in overall survival (International Collaborative Ovarian Neoplasm, 
Research, & Neoplasm, 2003; Trimbos et al., 2003). This strategy is felt to be best 
suited for women with more advanced ovarian cancer, particularly in cases with tumor 
spread beyond the abdominal cavity or disease so extensive that complete resection 
would be unlikely. A laparoscopic rating system has been validated to help a surgeon 
determine if surgery or chemotherapy should be performed first (Fagotti et al., 2013).   
A standard debulking surgery involves removing all reproductive organs and any 
cancerous tumors at the time of the surgery.  The standard, upfront chemotherapy 
regimen used in ovarian cancer is a platinum (carboplatin or cisplatin) and taxane (taxol 
or paritaxol) combination. Carboplatin is preferred over Cisplatin given the improved side 
effect profile.  While most of patients will respond well to this first line treatment, over 
80% will see the ovarian cancer return (Odunsi, 2015).  The average time to recurrence 
is approximately 24 months. The longer a disease free interval lasts, the better the 
prognosis.  If the ovarian cancer returns after a period of more than six months, it is still 
considered platinum-sensitive, and the standard of care is retreating the patient with a 
platinum-based doublet of chemotherapy (such as carboplatin/taxol or 
carboplatin/gemcitabine).   If the ovarian cancer returns within six months, it is 
concerned platinum-resistant and is associated with a poorer prognosis. Generally single 
agent chemotherapy treatment or clinical trials are recommended for platinum-resistant 
cases.  
The platinum/taxane chemotherapy regimen works by targeting all fast growing 
cells in the body.  Since the cancerous cells are fast growing, this approach is effective 
at killing cancer cells.  However, these drugs also kill other fast growing cells in the body 
(such as hair follicles, bone marrow, and the lining of the gastrointestinal tract). As a 
result healthy cells are damaged leading to highly toxic side effects.  Additionally, since 
there is a high degree of ovarian cancer recurrence and platinum resistance, oncologists 
are striving to find other more effective and less toxic treatment options. 
Two new classes of drugs have recently been approved for clinical use in ovarian 
cancer; antiangiogenesis drugs (i.e. bevacizumab) and PARP inhibitors (i.e. olaparib). 
Both agents have been approved in the recurrent setting.  Unfortunately neither of these 
two drugs replace the need for traditional cytotoxic chemotherapy, rather they add 
additional mechanisms of action and prolong progression-free survival intervals in 
recurrent cancers. Since these two drugs are new additions to the treatment arsenal, 
there are still ongoing clinical trials to test different applications for their use.  More 
information on the mechanisms of action and use of these drugs is in the Treatment 
section of this report. 
 
Ovarian Cancer Research Funding in the United States: Current State 
Ovarian cancer research in the US is primarily funded by two government 
sources: the National Cancer Institute (NCI) and the Department of Defense Ovarian 
Cancer Research Program (OCRP).  Table 2 shows the approximate distribution of 
cancer research funding by organization (Foundation for Women's Cancer, 2015).  Table 
3 describes the distribution of NCI funds, for the purpose of this evaluation we will 
assume that ovarian cancer funds follow a similar distribution. Table 4 provides a 
breakdown of OCRP funded projects, we will assume that the funding dollar amount is 
approximately proportional to the number of projects.  Each organization has a funding 
board that decides which research proposals are funded.  The Department of Defense 
proudly includes ovarian cancer survivors on the funding decision board (alongside 
doctors and researchers), however the NCI funding decision board includes mostly 
doctors and some pharmaceutical company executives. 
Table 2 - Ovarian Cancer Research Funding Sources (Foundation for Women's Cancer, 2015) 
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Table 3 - National Cancer Institute 2013 Fund Distributions (US Deparment of Health and Human Services, 
2013) 
 
Table 4 - US Department of Defense Ovarian Cancer Research Program (OCRP) Research Distribution from 
1997-2013 (US Department of Defense, 2014) 
 
Prevention 
 Scientists have been searching for environmental risk factors that could be 
contributing to the development of ovarian cancer.  Factors such as smoking or the 
Human Papilloma Virus, which contribute to other cancers, have been ruled out (Jayson 
et al., 2014).  However, approximately 23% of ovarian cancer patients have a genetic 
predisposition that has been identified (Toss et al., 2015).  Approximately 15% of women 
with epithelial ovarian cancer harbor a mutation on one of two breast cancer genes 
(BRCA1 and BRCA2). An additional 2% of ovarian cancer patients have a hereditary 
cancer syndrome known as Lynch Syndrome with deleterious mismatch repair (MMR) 
genes. Figure 2 shows genetic relationships that have been found for each of the 
different carcinoma types (Jayson et al., 2014).  Since this research is still very new, 
there are likely more genetic relationships that have yet to be identified. 
 Figure 2 - Epithelial Cancer subtypes and associated genetic mutations (Jayson et al., 2014) 
 Genetic testing and counseling can lead to some preventive measures.  The US 
Preventive Services Task Force advises genetic counseling for women with a personal 
or family history of breast and/or ovarian cancer (i.e. have a mother or sister with 
disease history) (US Preventive Services Task Force, 2013).  Women with BRCA1 or 
BRCA2 mutations or Lynch Disease are advised to consider a preventive bilateral 
salpingo-oophorectomy by the age of 40 or at completion of childbearing (ovary and 
fallopian tube removal) (Cashin-Garbutt, 2015).  While the salpingo-oophorectomy can 
prevent cancers originating on the ovaries or fallopian tubes, the procedure does not 
prevent primary peritoneal carcinoma (WebMD, 2013). Women with inherited risk of 
ovarian cancer who undergo prophylactic bilateral salpingo-oophorectomy have a 2-7% 
risk of peritoneal cancer (Powell, 2015). The National Comprehensive Cancer Network 
(NCCN) recommends that every ovarian cancer patient undergo genetic testing to better 
understand which gene mutations contribute to ovarian cancer, and also to identify 
which mutations the patient’s family members could be tested for (Cashin-Garbutt, 
2015).  However, in the very best case, this preventive measure can only prevent the 
approximately 23% of ovarian cancers that can be attributed to a genetic predisposition.  
More research is needed to estimate the causes and prevention measures for the 
remaining 77% of ovarian cancer caused by yet-to-be-discovered genetic mutations or 
other causes.  
 Recent research suggests that genetic profiling alone is not enough, and that 
other factors such as protein imbalance may play a role.  Researchers at MD Anderson 
and University of Leeds have found that two proteins (Plcγ1 and Grb2) compete for 
binding to a cell wall receptor FGFR2, which is responsible for signaling rapid cell growth 
(Timsah et al., 2015).  In in-vitro and animal in-vivo studies, cancerous cells tend to grow 
more when there is more Plcγ1 protein than Grb2 protein, where as cancerous cells 
grow less when Grb2 protein is in excess.  Looking at retrospective human data, 7-year 
overall survival is improved in women with increased Grb2 protein (40%) compared to 
women with less Grb2 protein (10%).  Another study of nearly 90 women with ovarian 
cancer found that women who tested negative for human leucocyte antigen (HLA-A2) 
had improved 5-year overall survival (50%) compared to women testing positive for HLA-
A2 (0% 5-year overall survival) (Gamzatova et al., 2006).  
 
Research Funding: Prevention 
 In order to determine best preventative measures, more research is needed to 
understand the underlying causes of ovarian cancer, especially for the approximately 
77% of ovarian cancer cases where genetic or other causes are still unknown.  The US 
Department of Defense OCRP designates a significant portion of research 
(approximately 52%) toward basic biological and genetic research.  However, National 
Cancer Institutes funds less to basic research, attributing barely 40% to cancer 
causation and biology combined.  The first recommendation is to increase funding 
toward basic and preventive research, specifically targeting and studying ovarian cancer 
cases for which the cause is unknown.  One recent study at the University of 
Washington (funded by OCRP) identified families with strong history of ovarian cancer 
that did not test positive for known genetic mutations linked to ovarian cancer.  Whole 
genetic sequencing was performed on the women in these families that did have ovarian 
cancer and similar mutations in a new cancer gene (called CHEK1) were identified (US 
Department of Defense, 2014). The NCI and OCRP should continue to strive to fund 
research that will help determine the causes for the majority of ovarian cancer cases that 
are still not known. 
 
Detection 
 Unfortunately, most cases of ovarian cancer have progressed and spread without 
presenting symptoms until the disease has advanced significantly.  Additionally, the 
symptoms that do present are usually vague, such as abdominal pain and 
gastrointestinal issues. This leads to multiple referrals and misdiagnoses, such as 
irritable bowel syndrome (IBS).  Due to the vague and delayed physical indicators of 
ovarian cancer, effective early detection mechanism would be a powerful way to catch 
ovarian cancer in earlier stages where survival rates are much higher (see Table 1). 
Cancer antigen (CA)-125 is currently the best marker available to indicate 
ovarian cancer activity. CA-125 is secreted by peritoneal surface cells in response to 
inflammation, as a result this test is not specific, and can be elevated for a number of 
reasons other than ovarian cancer. This also means that this lab value is often normal in 
early stage ovarian cancer. The UK National Institute for Health and Clinical Excellence 
(NICE) recommends that primary care providers order a blood test for CA-125 for all 
patients (especially women over 50 years) presenting IBD symptoms (Jayson et al., 
2014).  However, this recommendation has not been made in the United States due to 
the poor specificity of this marker. A large scale screening study completed in 2009 
showed that CA-125/ultrasound screening is not sensitive enough to be an effective 
ovarian cancer screening method for the general population (Buys et al., 2011).  Another 
large study performed by the University of Kentucky tested transvaginal ultrasound 
screening on high-risk women with a family history of disease. The study did identify  
some cancer cases at earlier stages, however still generated a high number of false 
positive cases, resulting in hundreds of unnecessary surgeries (van Nagell et al., 2011).  
Better ovarian cancer surveillance techniques are desperately needed.  
 
Research Funding: Detection 
At this point, there are no reliable screening techniques available for ovarian 
cancer.  If only half of the newly diagnosed Stage III ovarian cancer cases were detected 
at stage I, nearly 100,000 lives could be extended.  However, the NCI and OCRP 
designate only 8.4% and 11%, respectively, on detection and diagnosis research.  
Impressively, the OCRP includes ovarian cancer survivors in the funding board panels, 
another recommendation is to include high-risk women with family history of disease on 
these panels as well.  High-risk women also have a vested interest in ensuring that 
effective early detection mechanisms are in place. More research is needed to test more 
screening methods and define screening programs, especially for high-risk individuals 
like women with family history of ovarian cancer, and/or women who test positive for 
specific gene mutations.  
 
Treatment 
 With the advancement of genetic testing, better understanding of cancer and 
many ongoing clinical trials, the next ten years will likely mark a turning point in 
advances of many types of cancer, including ovarian cancer (Jayson et al., 2014; 
Lheureux et al., 2015).  This section highlights some of those advances ordered based 
on ease of implementation and strength of supporting evidence with the easiest best 
supported advances first.  
  
 
Intraperitoneal (IP) Chemotherapy Administration – new approach to a classic treatment 
In 2006, the National Cancer Institute issued a clinical announcement based on 
studies that showed evidence that platinum/taxol chemotherapy drugs, could be 
delivered straight to the abdomen using an intraperitoneal (IP) catheter to increase the 
median overall survival by nearly 16 months over the regular intravenous (IV) 
chemotherapy administration median overall survival (from 49.7 months to 65.6 months) 
(Armstrong et al., 2006).  Critics of this technique state the regimen is extremely toxic 
and only 42% of patients randomized to this treatment arm were able to complete all six 
cycles of their intended IP therapy. Even so, the data was analyzed on intent to treat and 
even if only a few cycles of IP therapy were given this survival benefit is astounding. 
Additionally, most toxicities experienced by women undergoing IP therapy are short 
term.  
Today, the IP method remains largely underutilized (Wright et al., 2015).  One 
recent New York Times article suspects that since this method involves generic drugs 
and devices, there are no companies willing to do large scale doctor trainings on 
implanting the catheters or devices required for IP delivery (Grady, 2015).  Since 
intraperitoneal ports require experience and expertise, doctors must become trained and 
proficient at this type of chemotherapy delivery. This remains a key barrier to utilization 
of this technique.  Since this treatment approach does not create a new “market 
opportunity,” companies have no reason to fund training on IP chemotherapy delivery.  
This would be a good application for the National Cancer Institute to fund trainings and 
tools to help oncologists to decide when to use IP and perfect technique. 
  
Anitangiogenic agents – restricting blood supply to cancer cells 
 Growing malignant tumors depend on formation of a blood supply and often 
divert blood from the otherwise healthy organs beside it, almost acting as a self-
generated parasite.  In order to stimulate the growth of this blood supply the tumor 
secretes vascular endothelial growth factor (VEGF). Some new drugs target restricting 
the tumor’s ability to grow a blood supply by targeting VEGF.  An anti-VEGF monoclonal 
antibody called bevacizumab (Avastin®, Genentech/Roche) is now FDA approved for 
use both in conjunction with the standard platinum chemotherapy, and as a maintenance 
drug in ovarian cancer recurrence.  A drug called pazopanib (Votrient®, GSK/Novartis) is 
a multi-kinase inhibitor that also targets the VEGF growth factor, and has also been 
tested alongside chemotherapy in ovarian cancer patients. These drugs are referred to 
as targeted therapies and have different side effects than standard chemotherapy. 
These drugs do not supersede the need for standard, cytotoxic chemotherapy.  Rather 
these treatments are add-ons to the current first-line treatments in hopes of extending 
the period of progression free survival (PFS). 
 
Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) 
 PARP is a naturally occurring enzyme that participates in DNA repair.  A PARP 
inhibitor, olaparib (Lynparza®, AstraZenica) and has shown impressive tumor reduction 
specifically in patients with BRCA1 or BRAC2 mutations.  The proposed mechanism of 
action is that reducing PARP levels reduces the ability for cancer cells to undergo DNA 
repair, and thereby stops cancer growth. These drugs are being targeted at BRCA 
mutated women as the BRCA mutation in homologous recombination repair makes 
these women especially vulnerable to further DNA damage. This newly available 
targeted therapy for women with BRCA highlights the importance of genetic testing to 
determine treatment options for a patient. This drug could be combined during 
chemotherapy, but adds to the overall toxicity.  It has also been used as a maintenance 
therapy to prevent recurrence.  Ongoing clinical trials continue to investigate the best 
use of olaparib and other PARP inhibitors. 
 
Therapeutic Cancer Vaccines – training the immune system to attack the cancer 
 Natural immune responses to cancerous cells in ovarian cancer patients have 
been found in blood tests during diagnosis (Kandalaft, Powell, Singh, & Coukos, 2011), 
which gives hope that effective vaccines can be designed to help the body combat 
ovarian cancer.  A search of clinicaltrials.gov for condition: “ovarian cancer” and 
keyword: “vaccine” yields 40 completed clinical trials and 46 ongoing clinical trials.  
Additionally, drug company websites are boasting many more candidates in early stages 
of pre-clinical development (PhRMA, 2013).  Appendix A describes the current state of 
active and recruiting clinical trials for ovarian cancer as of August 2015.  These 
treatment approaches are still in early stages of research, and are typically only tried if a 
patient has already tried the other therapies listed above.  However if any of these 
methods are successful, it could be a potential new way of treating ovarian cancer in the 
future.    
 
Tumor Associated Antigen/Peptide Vaccines  
A number of cancer specific peptides and tumor-associated antigens (TAAs) 
have been identified, that could help design a vaccine to train the immune system to 
destruct any cancer cells with specific antigen markers.  Some such TAAs are called 
cdr2, p53, HER2/neu, mesothelin, folate receptor-α, NY-ESO-1, MAGE melanoma 
antigen, Sp17, NY-ESO-1, MUC1, and MUC15 (also know as CA-125) (Kandalaft et al., 
2011; Odunsi, 2015).  This list is not comprehensive and additional antigen targets are 
actively being discovered.  One of two approaches are typically taken for this vaccination 
approach, either: a) one or multiple peptide or proteins are made and injected into the 
patient to generate an immune response, or b) cells from the patient’s whole tumor are 
used to make a customized vaccine designed to train the patient’s immune system to 
attack the specific antigens present on his/her own tumor. In either case, the approach is 
to train the immune system to identify those cancer cells and kill the cells using the 
body’s own immune system.  By training the immune system, the aim is to help the body 
learn to fight existing cancer and prevent new cancer from recurring.  If standard 
antigens can be identified, the vaccine could be more inexpensive and have fewer side 
effects.  One downside is that many cancer patients are immunocompromised, 
particularly after undergoing multiple cycles of chemotherapy, so the immune system 
may not always be strong enough to generate a strong immune response. Therefore, 
vaccines are often accompanied with an adjuvant or immune modulator to promote a 
stronger immune response (Kandalaft et al., 2011). There may also be a benefit in using 
vaccines prior to initiation of multiple chemotherapy regimens to allow the immune 
system to be at its strongest. 
 
Modified Virus Vaccine 
Many viruses are known to generate a good immune response, and some of 
these viruses can be either genetically modified to present one or more of the cancer 
antigens listed above.  Alternatively, the virus can be used to infect a patient’s tumor cell 
to create a personalized version of a modified virus vaccine.  Both of these approaches 
are being used for multiple modified virus vaccines currently in trials, and the aim is to 
generate better immune responses than the antigen-alone vaccines.  Some of the 
viruses used include herpes simplex, measles, small pox and others (Odunsi, 2015). 
 
 
Dendritic cell vaccines – training immune response outside the body 
Dendritic cell vaccines are another approach that is being tested to train a 
patient’s immune system outside of the patient’s body.  For this vaccine type, a patient’s 
dendritic cells are collected and treated either with RNA electroporation or with the 
patient’s own tumor to “train” these cells to recognize and fight cancerous cells.  This 
process of removing and priming dendritic cells is more individualized to the patient, 
however more expensive and complex to manufacture, distribute and store (McGreevey, 
2014). As of 2011, three of six clinical trials to date have shown greater remission 
periods for ovarian cancer patients treated with dendritic cell vaccines (Kandalaft et al., 
2011), sparking numerous follow on clinical trials. 
 
Plasmid DNA vaccine  
 Plasmid DNA vaccines take a similar approach to the Tumor Associate 
Antigen/Peptide vaccines, however, rather than using the antigen protein, the vaccine 
consists of a plasmid DNA construct that contains “information” for the patient’s own 
cells to generate the antigen inside the body for an immune response.  This is a 
relatively new vaccination approach, and initial clinical trials showed low immune 
response. This is likely due to insufficient plasmid DNA concentrations(Bei & Scardino, 
2010), and further clinical trials are investigating dose response relationships. 
 
Adoptive T-cell Therapy – increasing the concentration of anti-cancer T-cells 
 Rather than train the immune system to fight cancer, another approach is to 
boost the concentration of a patient’s own T-cells.  Approximately 55% of ovarian cancer 
patients develop reactive anti-cancer T-cells that can be found in tumor or ascites 
(Zsiros, Tanyi, Balint, & Kandalaft, 2014). These T-cells can then be grown and 
expanded and the most powerful T-cells are selected and expanded further.  Higher 
concentrations of the best T-cells are infused back into the patient.  This method has 
shown promising results in small scale tests, with 100% 3-year survival rates (Kandalaft 
et al., 2011).  In some cases, where an original tumor could not be restored or the 
patient did not have spontaneous reactive T-cells, T-cells have been able to be adopted 
using genetic engineered to target specific cancer-type antigens, and then expand the T-
cells for infusion. This approach is similar to the dendritic cell vaccine approach, 
“training” the T-cells outside of the body. 
 
Research Funding: Treatment 
 Pharmaceutical companies are actively researching new treatments for ovarian 
cancer, partly because current standard of care is toxic with high recurrence rates, and 
partly because ovarian cancer is considered and orphan disease.  So, effective 
therapies have the opportunity to get “fast-tracked” through regulatory agency approvals 
if the treatment looks promising.  Because there is ample incentive for treatment 
research through private market funds, the NCI and OCRP should reserve treatment 
research funds for cases where there is great mortality improvement with little to no 
market incentive (such as intraperitoneal chemotherapy).  Considering that the 22.4% 
and 18% of the NCI and OCRP funds are dedicated to treatment research, these 
projects should be re-evaluated and re-directed to basic research to guide prevention or 
earlier detection.  Additionally, the NCI should reconsider including pharmaceutical 
executives on the funding boards, and consider including cancer survivors and high-risk 
family members. 
 
 
 
 
Conclusion 
 In conclusion, ovarian cancer mortality is relatively high due to late detection of 
advanced cancer and high recurrence rates on the current chemotherapy regimens.  As 
the two main funders of ovarian cancer research, the National Cancer Institute (NCI) and 
Ovarian Cancer Research Program (OCRP) have an opportunity to influence ovarian 
cancer mortality by redirecting how research is funded for ovarian cancer prevention, 
detection and treatment in the following ways: 
• Increase the proportion of funding to basic biology, specifically targeting to better 
understand the cause of the 77% of ovarian cancers for which there is no clear 
genetic or causal factor. 
• Increase funding to detection and diagnosing studies.  Since there are no 
environmental factors that clearly lead to prevention measures (i.e. smoking or 
vaccination), early detection is currently the most promising way to reduce 
mortality, and gives the most “bang for the buck” if an effective screening 
program can be developed. 
• Re-evaluate funds directed to treatments and only fund treatment options that 
can be applied quickly, with high mortality improvement potential and low 
financial incentive for companies.  Other research activities (such as 
immunotherapeutic cancer vaccines) can be deferred to the companies with 
financial incentive to develop breakthrough treatments. 
• Both organizations should reconsider how their funding boards are assembled, 
increasing representation of cancer patients and their family members, and 
decreasing representation from pharmaceutical companies and others with 
financial incentive for how research money is allocated. 
 
As the primary ovarian cancer research funders, the National Cancer Institute 
and Department of Defense Ovarian Cancer Research Program have the opportunity to 
increase research in basic prevention and detection measures.  Alongside active 
industry investment in novel treatment therapies, we have reason to be optimistic that 
ovarian cancer morbidity will be reduced through new prevention, detection and 
therapeutic advances. 
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Appendix 1 – Ongoing clinical trials for ovarian cancer vaccines, categorized by Vaccine Type (clinicaltrials.gov; August 7, 2015) 
 
Tumor Associated Antigen/Peptide Vaccine Clinical Trials 
NCT01606241 
Vaccine	  Therapy	  and	  Cyclophosphamide	  in	  Treating	  Patients	  With	  
Stage	  II-­‐III	  Breast	  or	  Stage	  II-­‐IV	  Ovarian,	  Primary	  Peritoneal,	  or	  
Fallopian	  Tube	  Cancer Active 
Multi-­‐epitope	  Folate	  Receptor	  
Alpha	  Peptide	  Vaccine 
NCT01580696 Phase	  I/IIa	  Trial	  of	  Folate	  Binding	  Protein	  Vaccine	  in	  Ovarian	  Cancer Active E39	  peptide	  vaccine 
NCT01551745 Salvage	  Ovarian	  FANG	  Vaccine	  +	  Bevacizumab Active 
FANG	  vaccine,	  personalized	  
tumor	  antigen	  vaccine 
NCT01867086 Salvage	  Ovarian	  FANG	  Vaccine	  +	  Carboplatinum Active 
FANG	  vaccine,	  personalized	  
tumor	  antigen	  vaccine 
NCT00373217 
Vaccine	  Therapy,	  Paclitaxel,	  and	  Carboplatin	  in	  Treating	  Patients	  Who	  
Are	  Undergoing	  Surgery	  for	  Stage	  III	  or	  Stage	  IV	  Ovarian	  Cancer,	  
Primary	  Peritoneal	  Cancer,	  or	  Fallopian	  Tube	  Cancer Active 
FBP	  peptides/tetanus	  toxoid	  
helper	  peptide 
NCT00857545 
OPT-­‐821	  With	  or	  Without	  Vaccine	  Therapy	  in	  Treating	  Patients	  With	  
Ovarian	  Epithelial	  Cancer,	  Fallopian	  Tube	  Cancer,	  or	  Peritoneal	  Cancer	  
in	  Second	  or	  Third	  Complete	  Remission Active 
Polyvalent	  Antigen-­‐KLH	  
Conjugate	  Vaccine 
NCT01309230 
Trial	  of	  Adjuvant	  FANG®„¢	  Vaccine	  for	  High	  Risk	  Stage	  III/IV	  Ovarian	  
Cancer Active 
FANG,	  personalized	  tumor	  
antigen	  vaccine 
NCT01522820 
Vaccine	  Therapy	  With	  or	  Without	  Sirolimus	  in	  Treating	  Patients	  With	  
NY-­‐ESO-­‐1	  Expressing	  Solid	  Tumors Active 
DEC-­‐205/NY-­‐ESO-­‐1	  Fusion	  
Protein	  CDX-­‐1401 
NCT00660101 
Trial	  of	  Autologous,	  Hapten-­‐Modified	  Vaccine,	  OVAX,	  in	  Patients	  With	  
Relapsed	  Stage	  III	  or	  IV	  Ovarian	  Cancer Active 
Ovax,	  personalized	  tumor	  
antigen	  vaccine 
NCT01223235 
Polyvalent	  Vaccine-­‐KLH	  Conjugate	  +	  Opt-­‐821	  Given	  in	  Combination	  
With	  Bevacizumab Active 
polyvalent	  vaccine-­‐KLH	  
conjugate	  +	  OPT-­‐821 
NCT01095848 
A	  Phase	  I	  Safety	  Study	  of	  a	  Cancer	  Vaccine	  to	  Treat	  HLA-­‐A2	  Positive	  
Advanced	  Stage	  Ovarian,	  Breast	  and	  Prostate	  Cancer Active DPX-­‐0907 
NCT01416038 
Phase	  1-­‐2	  Study	  of	  a	  Cancer	  Vaccine	  to	  Treat	  Patients	  With	  Advanced	  
Stage	  Ovarian,	  Fallopian	  or	  Peritoneal	  Cancer Active DPX-­‐Survivac 
NCT01248273 
Unimolecular	  Pentavalent	  (Globo-­‐H-­‐GM2-­‐sTn-­‐TF-­‐Tn)	  Immunization	  of	  
Patients	  With	  Epithelial	  Ovarian,	  Fallopian	  Tube,	  or	  Peritoneal	  Cancer	  
in	  First	  Remission Active 
Globo-­‐H-­‐GM2-­‐sTn-­‐TF-­‐Tn-­‐KLH	  
conjugate,	  plus	  the	  
immunological	  adjuvant	  QS-­‐21 
NCT01536054 
Sirolimus	  and	  Vaccine	  Therapy	  in	  Treating	  Patients	  With	  Stage	  II-­‐IV	  
Ovarian	  Epithelial,	  Fallopian	  Tube,	  or	  Primary	  Peritoneal	  Cavity	  Cancer Active 
ALVAC(2)-­‐NY-­‐ESO-­‐1	  
(M)/TRICOM	  vaccine 
NCT01519817 
Open	  Label	  Study	  to	  Evaluate	  the	  Safety	  and	  Tolerability	  of	  GI-­‐6301	  
(Whole	  Heat-­‐Killed	  Recombinant	  Yeast	  Modified	  to	  Express	  Brachyury	  
Protein)	  in	  Adults	  With	  Solid	  Tumors Active 
GI-­‐6301	  (Whole	  Heat-­‐Killed	  
Recombinant	  Yeast	  Modified	  
to	  Express	  Brachyury	  Protein) 
NCT02019524 
Phase	  Ib	  Trial	  of	  Two	  Folate	  Binding	  Protein	  Peptide	  Vaccines	  (E39	  and	  
J65)	  in	  Breast	  and	  Ovarian	  Cancer	  Patients Recruiting E39	  vaccine	  /	  J65	  vaccine 
NCT02270372 
Study	  of	  ONT-­‐10	  and	  Varlilumab	  to	  Treat	  Advanced	  Ovarian	  or	  Breast	  
Cancer Recruiting 
ONT-­‐10	  (targeting	  MUC1	  
antigen) 
NCT02166905 
DEC-­‐205/NY-­‐ESO-­‐1	  Fusion	  Protein	  CDX-­‐1401,	  Poly	  ICLC,	  and	  IDO1	  
Inhibitor	  INCB024360	  in	  Treating	  Patients	  With	  Ovarian,	  Fallopian	  
Tube,	  or	  Primary	  Peritoneal	  Cancer	  in	  Remission Recruiting 
DEC-­‐205/NY-­‐ESO-­‐1	  Fusion	  
Protein	  CDX-­‐1401 
NCT01621542 Clinical	  Study	  of	  WT2725	  in	  Patients	  With	  Advanced	  Malignancies Recruiting WT2725	  (targets	  WT1) 
NCT00553683 
Cyclophosphamide,	  Radiation	  Therapy,	  and	  Poly	  ICLC	  in	  Treating	  
Patients	  With	  Unresectable,	  Recurrent,	  Primary,	  or	  Metastatic	  Liver	  
Cancer Active 
Personalized	  Tumor	  antigen	  
Vaccination 
Dendritic	  Cell	  Vaccine	  Clinical	  Trials	  
NCT00799110	  
Vaccination	  of	  Patients	  With	  Ovarian	  Cancer	  With	  Dendritic	  
Cell/Tumor	  Fusions	  With	  Granulocyte	  Macrophage	  Colony-­‐stimulating	  
Factor	  (GM-­‐CSF)	  and	  Imiquimod	   Active	  
Dedritic	  Cell	  Vaccine/Tumor	  
Fusion	  
NCT01312376	  
Autologous	  T-­‐Cells	  Combined	  With	  Autologous	  OC-­‐DC	  Vaccine	  in	  
Ovarian	  Cancer	   Active	   OC-­‐DC	  vaccine	  
NCT01312389	  
A	  Clinical	  Trial	  of	  Autologous	  Oxidized	  Tumor	  Cell	  Lysate	  Vaccine	  For	  
Recurrent	  Ovarian,	  Fallopian	  Tube	  or	  Primary	  Peritoneal	  Cancer	   Active	  
Autologous	  Oxidized	  Tumor	  
Cell	  Lysate	  Vaccine	  
NCT02107378	  
Efficacy	  of	  DCVAC/OvCa	  Plus	  Standard	  of	  Care	  in	  Relapsed	  Platinum	  
Resistant	  Epithelial	  Ovarian	  Carcinoma	   Active	   DCVAC/OvCa	  
NCT01456065	   Safety	  of	  Active	  Immunotherapy	  in	  Subjects	  With	  Ovarian	  Cancer	   Active	   Procure	  DC	  vaccine	  
NCT02111941	  
Vaccine	  Therapy	  in	  Treating	  Patients	  With	  Stage	  IIIC-­‐IV	  Ovarian	  
Epithelial,	  Fallopian	  Tube,	  or	  Primary	  Peritoneal	  Cavity	  Cancer	  
Following	  Surgery	  and	  Chemotherapy	   Recruiting	  
Multi-­‐epitope	  Folate	  Receptor	  
Alpha-­‐loaded	  Dendritic	  Cell	  
Vaccine	  
NCT00703105	   Ovarian	  Dendritic	  Cell	  Vaccine	  Trial	   Recruiting	   Ontak	  DC	  vaccine	  
NCT02452775	   Autologous	  OC-­‐L	  Vaccine	  and	  Ovarian	  Cancer	   Recruiting	   OC-­‐L	  
NCT01132014	   Autologous	  OC-­‐DC	  Vaccine	  in	  Ovarian	  Cancer	   Recruiting	   OCDC	  
Modified	  Virus	  Vaccines	  
NCT02179515	  
Safety	  and	  Tolerability	  of	  a	  Modified	  Vaccinia	  Ankara	  (MVA)-­‐Based	  
Vaccine	  Modified	  to	  Express	  Brachyury	  and	  T-­‐cell	  Costimulatory	  
Molecules	  (MVA-­‐Brachyury-­‐TRICOM)	   Active	  
Modified	  Vaccinia	  Ankara	  
(MVA)-­‐Based	  Vaccine	  
NCT00408590	  
Recombinant	  Measles	  Virus	  Vaccine	  Therapy	  and	  Oncolytic	  Virus	  
Therapy	  in	  Treating	  Patients	  With	  Progressive,	  Recurrent,	  or	  
Refractory	  Ovarian	  Epithelial	  Cancer	  or	  Primary	  Peritoneal	  Cancer	   Active	  
carcinoembryonic	  antigen-­‐
expressing	  measles	  virus	  
NCT00769613	  
Emergency	  Use	  of	  Donor	  Lymphocytes	  in	  Treating	  Patients	  Who	  Have	  
Undergone	  Donor	  Stem	  Cell	  Transplant	  and	  Have	  Cytomegalovirus	  
Infections	   Active	  
cytomegalovirus	  IE-­‐1-­‐specific	  
cytotoxic	  T	  lymphocytes	  
NCT02275039	  
p53MVA	  Vaccine	  and	  Gemcitabine	  Hydrochloride	  in	  Treating	  Patients	  
With	  Recurrent	  Ovarian	  Epithelial	  Cancer	   Recruiting	  
modified	  vaccinia	  virus	  ankara	  
vaccine	  expressing	  p53	  
NCT01997190	  
Intrapleural	  AdV-­‐tk	  Therapy	  in	  Patients	  With	  Malignant	  Pleural	  
Effusion	   Recruiting	   AdV-­‐tk	  (herpes	  simplex	  virus)	  
NCT00088413	  
PANVAC-­‐V	  and	  PANVAC-­‐F	  Vaccines	  Plus	  Sargramostim	  to	  Treat	  
Advanced	  Cancer	   Active	  
PANVAC-­‐V/PANVAC-­‐F	  (small	  
pox	  and	  Foulpox)	  
Plasmid	  DNA	  Vaccines	  
NCT01322802	  
Vaccine	  Therapy	  in	  Treating	  Patients	  With	  Stage	  III-­‐IV	  or	  Recurrent	  
Ovarian	  Cancer	   Active	  
pUMVC3-­‐hIGFBP-­‐2	  multi-­‐
epitope	  plasmid	  DNA	  vaccine	  
NCT00436254	  
Vaccine	  Therapy	  With	  Sargramostim	  (GM-­‐CSF)	  in	  Treating	  Patients	  
With	  Her-­‐2	  Positive	  Stage	  III-­‐IV	  Breast	  Cancer	  or	  Ovarian	  Cancer	   Active	   pNGVL3-­‐hICD	  vaccine	  
NCT01376505	   Vaccine	  Therapy	  in	  Treating	  Patients	  With	  Metastatic	  Solid	  Tumors	   Recruiting	   HER-­‐2	  vaccine	  
 
